van der Pol, Simon http://orcid.org/0000-0003-1784-1001
Garcia, Paula Rojas http://orcid.org/0000-0003-4212-5445
Postma, Maarten J. http://orcid.org/0000-0002-6306-3653
Villar, Fernando Antoñanzas http://orcid.org/0000-0001-6122-9130
van Asselt, Antoinette D. I. http://orcid.org/0000-0001-7705-9906
Funding for this research was provided by:
Innovative Medicines Initiative (820755)
Article History
Accepted: 2 June 2021
First Online: 15 July 2021
Declarations
:
: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement no. 820755. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Accelerate Diagnostics S.L., Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl and The Wellcome Trust Limited. This paper reflects only the authors’ view, not that of the funder or supporting organizations.
: Maarten J. Postma received grants and honoraria from various pharmaceutical companies all unrelated to this research, except those underlying the IMI EU VALUE-Dx project underlying this work. Simon van der Pol, Paula Rojas Garcia, Fernando Antoñanzas Villar and Antoinette D.I. van Asselt have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The datasets generated during and/or analysed during the current study are available from GitHub:ExternalRef removed.
: The R code used for the current study is available from GitHub:ExternalRef removed.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by SvdP, PRG and ADIvA. The first draft of the manuscript was written by SvdP and PRG and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.